Vanguard Global Advisers
CABA icon

Vanguard Global Advisers’s Cabaletta Bio CABA Stock Holding History

Vanguard Global Advisers’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$178K Buy
57,372
+21,621
+60% +$71.1K ﹤0.01% 2549
2026
Q1 		$96.2K Buy
+35,751
New +$99.3K ﹤0.01% 2746

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Global Advisers's CABA Position: Q2 2026 in Review

Vanguard Global Advisers increased its Cabaletta Bio (CABA) stake by 60% in Q2 2026, buying an estimated $71.1K and bringing the position to 57,372 shares worth $178K. The position accounts for ﹤0.01% of the portfolio, ranked #2549.

Vanguard Global Advisers first reported a position in CABA in Q1 2026 and has held it in 2 quarters since. 140 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • Vanguard Global Advisers held 57,372 shares of Cabaletta Bio worth $178K as of Q2 2026.
  • Vanguard Global Advisers bought 21,621 Cabaletta Bio shares in Q2 2026, an estimated $71.1K.
  • Cabaletta Bio made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2549 holding.
  • Vanguard Global Advisers first reported a position in Cabaletta Bio in Q1 2026 and has held it in 2 quarters since.
  • 140 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.